The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias

Minegishi, Yuji; Sudoh, Junko; Kuribayasi, Hideaki; Mizutani, Hideki; Seike, Masahiro; Azuma, Arata; Yoshimura, Akinobu; Kudoh, Shoji; Gemma, Akihiko

doi:10.1016/j.lungcan.2010.04.014

Cited by 127 publications

(154 citation statements)

References 29 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…The incidence of acute exacerbation of ILD with nab-paclitaxel in the present study was 7.7%. Although there was no significant difference in the incidence of ILD between nab-paclitaxel and sb-paclitaxel, it was relatively lower with nab-paclitaxel compared with sb-paclitaxel, and almost equal to the previously reported incidence of acute exacerbation in association with sb-paclitaxel (2,3). In addition, Cremophor EL ® (BASF, Ludwigshafen am Rhein, Germany), which is contained in sb-paclitaxel for dissolution, is known to increase hypersensitivity, which may lead to acute exacerbation of ILD (13).…”

Section: Discussioncontrasting

confidence: 48%

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Yasuda

Nomizo

Ozasa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab-) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent-based (sb-) paclitaxel in patients with advanced non-small-cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab-paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab-paclitaxel (n=14) or sb-paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab-paclitaxel and 3/14 patients (21.4%) receiving sb-paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab-paclitaxel with that of sb-paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

show abstract

Section: Discussioncontrasting

confidence: 48%

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Yasuda

Nomizo

Ozasa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The combination of carboplatin with etoposide and of carboplatin with paclitaxel was efficacious in two small studies of patients with IIPs and small cell lung carcinoma and non-small cell lung carcinoma (NSCLC), respectively. When the authors integrated the two groups, in 35 patients, they observed 10 AEs, but in only two cases was there temporal linkage to this specific chemotherapy regimen [129,130].…”

Section: Lung Cancermentioning

confidence: 99%

Comorbidities in interstitial lung diseases

2017

View full text Add to dashboard Cite

Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.

show abstract

“…The safety and efficacy of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin is uncertain, although the combination of carboplatin and paclitaxel is the most common regimen for treating NSCLC patients with ILD (1)(2)(3). Lung cancer is the leading cause of cancer-related mortality worldwide (4), although the treatment of patients with NSCLC is gradually improving (5).…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

Niwa

Nakahara

Yokoba

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. There are few established treatments for patients with non-small-cell lung cancer (NSCLC) with interstitial lung disease (ILD). The safety and efficacy of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin is uncertain, although the combination of carboplatin and paclitaxel is the most common regimen for treating NSCLC patients with ILD. A total of 9 NSCLC patients with ILD, treated between April 2013 and March 2016, were retrospectively investigated. Carboplatin (AUC 5-6) was administered on day 1 and nab-paclitaxel on days 1, 8 and 15, every 4-6 weeks. The median age of the patients upon initiating chemotherapy was 67 years. The pathological examination revealed 6 patients with squamous cell carcinoma, and 6 patients exhibited the typical pattern of ILD. The response rate was 55.6%, and the median progression-free and overall survival time was 174 and 344 days, respectively. Acute exacerbation of ILD was not observed in any of the patients, and febrile neutropenia developed in 3 patients (3/9, 33.3%). Thus, treatment with carboplatin plus nab-paclitaxel was found to be safe and effective for NSCLC patients with ILD, although management of hematological adverse events, such as febrile neutropenia, was required. However, these encouraging results require confirmation by a large-scale clinical trial.

show abstract

The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias

Cited by 127 publications

References 29 publications

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Comorbidities in interstitial lung diseases

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

Contact Info

Product

Resources

About